Drug approval: Selpercatinib and pralsetinib  - RET-altered thyroid cancer

Bull Cancer. 2021 Sep 28:S0007-4551(21)00301-5. doi: 10.1016/j.bulcan.2021.05.009. Online ahead of print.NO ABSTRACTPMID:34598787 | DOI:10.1016/j.bulcan.2021.05.009
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research